La vendita allo scoperto per Petros Pharma dà agli investitori un'idea del grado in cui gli investitori stanno scommettendo sul declino delle azioni di Petros Pharma. I dati relativi alle vendite allo scoperto vengono aggiornati ogni due settimane.

Petros Pharma (NASDAQ:PTPI) Azioni, Report sulle vendite allo scoperto

Petros Pharmaceuticals

Petros Pharmaceuticals Inc is a men's health pharmaceutical company. It focuses on therapeutics that promote medication adherence, tolerability, and preservation of male organic function. The company's operating segment includes Prescription Medications and Medical Devices. It generates maximum revenue from the Medical Devices segment. The Prescription Medications segment consists of operations related to vacuum erection devices, which are sold domestically and internationally.

Petros Pharmaceuticals, Inc. - Common Stock

Petros Pharmaceuticals Inc

PT CHANDRA ASRI PACIFIC by PT Chandra Asri Pacific Tbk

PT Chandra Asri Pacific Tbk

Raymond James analyst Rick Patel maintains Ralph Lauren (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RL#NYSE">RL</a>) with a Outperform and raises the price target from $215 to $235.

News

Price Target

Analyst Ratings

Raymond James Maintains Outperform on Ralph Lauren, Raises Price Target to $235

ADC Therapeutics Faces Competitive Oncology Market But Analyst Sees 100% Upside &#8211; Here&#8217;s Why
Stephens analyst has initiated coverage on ADC Therapeutics SA (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ADCT#NYSE">ADCT</a>), a commercial-stage oncology-focused biotechnology company developing antibody-drug conjugates (ADCs) for patients with hematological malignancies and solid tumors.
The company's lead asset, Zynlonta (loncastuximab tesirine-Ipyl), is a CD19-directed ADC with a pyrrolobenzodiazepine (PBD) payload.
The drug received accelerated FDA approval in January 2021 for adult patients with relapsed/refractory (r/r) large B-cell lymphoma (DLBCL) after two or more lines of systemic therapy.
Also Read:&nbsp;<a href="https://www.benzinga.com/general/biotech/23/07/33324772/adc-therapeutics-pulls-plug-on-mid-stage-zynlonta-study-in-untreated-lymphoma-patients-after-pati">ADC Therapeutics Pulls Plug On Mid-Stage Zynlonta Study In Untreated Lymphoma Patients After Patient Deaths</a>
The analyst points out that Zynlonta has faced stiff competition, and while it reached an annualized revenue run rate of about $80 million at its peak in the first quarter of 2023, it has struggled in the market.
The analyst expects Zynlonta&#8217;s peak revenue in the third-line treatment setting to reach $110 million in the U.S. by 2032.
The analyst&#8217;s outlook depends on the expectation that Zynlonta will receive approval for use in second-line treatment for diffuse large B-cell lymphoma (DLBCL), based on positive results from the LOTIS-5 and LOTIS-7 clinical trials.
Preclinical data suggests that combining Zynlonta with rituximab, an anti-CD20 antibody, may improve tumor control and provide longer-lasting results. The company is looking to expand Zynlonta&#8217;s use to treat second-line DLBCL and indolent lymphomas, either alone or in combination with other treatments.
Although the analyst supports Zynlonta's approval for second-line DLBCL, they are cautious about its revenue potential in this space.
Stephens has initiated with an Overweight rating, <a href="https://www.benzinga.com/quote/ADCT/analyst-ratings">with a price target of $6</a>.
The second-line DLBCL market is competitive with many treatment options available. However, the analyst sees value in Zynlonta due to its promising efficacy, with an 80% overall response rate and a 50% complete response rate. They estimate that Zynlonta could contribute about $172 million in revenue from second-line DLBCL by 2032.
In addition, ADCT has a broad pipeline of antibody-drug conjugates (ADCs) targeting other solid tumor indications, giving the company multiple opportunities for growth outside of Zynlonta.
Price Action: ADCT stock is up 0.68% at $2.95 at the last check on Friday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/general/health-care/24/11/41845345/baxter-expects-hurricane-helene-aftermath-to-impact-near-term-financial-outlook">Baxter Expects Hurricane Helene Aftermath To Impact Near-Term Financial Outlook</a></li>
</ul>

Analyst Color

Biotech

Health Care

Initiation

Trading Ideas

General

ADCT

ADC Therapeutics Faces Competitive Oncology Market But Analyst Sees 100% Upside - Here's Why

Barclays analyst Matt Miksic maintains Tandem Diabetes Care (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TNDM#NASDAQ">TNDM</a>) with a Overweight and raises the price target from $58 to $60.

TNDM

Barclays Maintains Overweight on Tandem Diabetes Care, Raises Price Target to $60

Barclays analyst Andrew Mok maintains Privia Health Gr (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PRVA#NASDAQ">PRVA</a>) with a Equal-Weight and raises the price target from $19 to $21.

PRVA

Barclays Maintains Equal-Weight on Privia Health Gr, Raises Price Target to $21

Raymond James analyst Joseph Altobello maintains Planet Fitness (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PLNT#NYSE">PLNT</a>) with a Strong Buy and raises the price target from $92 to $110.

PLNT

Raymond James Maintains Strong Buy on Planet Fitness, Raises Price Target to $110

Trump Media &amp; Technology Group (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DJT#NASDAQ">DJT</a>) stock soared Friday after President-elect Donald Trump said he has no plans to sell his stake in the Truth Social parent.
Trump denied rumors of a potential share sale in a post on Truth Social, calling them "fake, untrue, and probably illegal," likely spread by market manipulators or short sellers. He emphasized, "I have no intention of selling."
<figure class="wp-block-image size-large"><img loading="lazy" decoding="async" width="1024" height="553" src="https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/08122722/Trump-Truth-1024x553.png" alt="" class="wp-image-638169" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/08122722/Trump-Truth-1024x553.png 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/08122722/Trump-Truth-300x162.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/08122722/Trump-Truth-768x415.png 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/08122722/Trump-Truth-1536x829.png 1536w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/08122722/Trump-Truth.png 1850w" sizes="(max-width: 1024px) 100vw, 1024px" /></figure>
Shares of the company were trading 16.23% higher to $32.19 midday Friday. 
Also Read: <a href="https://www.benzinga.com/government/regulations/24/11/41845483/taiwan-semiconductor-us-expansion-plans-unfazed-by-trump-win-report">Taiwan Semiconductor US Expansion Plans Unfazed by Trump Win: Report</a>
Trump Media stock plunged 23% Thursday. The sharp decline followed a 6% surge the previous day, driven by Trump's political return, according to Reuters. 
On Tuesday, Trump Media reported a <a href="https://www.benzinga.com/news/earnings/24/11/41760961/djt-stock-volatile-on-election-day-donald-trumps-media-company-reports-q3-earnings-growth-initiativ">third-quarter net sales</a> decline of 6% to $1.01 million. The company said advertising on the Truth Social platform drove the topline.
The company reported a loss of 10 cents per share compared to a loss of 30 cents per share in last year&#8217;s third quarter.
Despite recent losses and low revenue, Trump Media's market cap now exceeds $5.5 billion.
Trump Media stock has gained 75% year-to-date, gaining traction from Trump&#8217;s decision to hold onto <a href="https://www.benzinga.com/government/24/10/41606911/whats-going-on-with-trump-media-technology-stock-on-tuesday">his majority stake</a> in the company despite the expiry of the lockup period and his improving position as a presidential candidate running against Vice President Kamala Harris. 
Also Read:
<ul>
<li><a href="https://www.benzinga.com/news/earnings/24/11/41844770/madison-square-garden-q1-revenue-drops-concerts-impress">Madison Square Garden Q1: Revenue Drops, Concerts Impress</a></li>
</ul>
Photo via Shutterstock.

Government

Media

Trump Says He Won't Sell Trump Media Stock

<a href="https://news.bloomberglaw.com/health-law-and-business/american-jetblue-alliance-breakup-upheld-by-appeals-court">https://news.bloomberglaw.com/health-law-and-business/american-jetblue-alliance-breakup-upheld-by-appeals-court</a>
<ul>
<li>Decision affirms ruling that ended airline partnership</li>
<li>American Airlines had appealed, arguing court misapplied law</li>
</ul>
A partnership between American Airlines Group Inc. and JetBlue Airways Corp. violated US antitrust law, an appeals court ruled, affirming a lower court decision to end the alliance.
In a unanimous <a href="https://assets.bwbx.io/documents/users/iqjWHBFdfxIU/rXwJ_Vy85PrU/v0">decision</a>, a three-judge panel on the 1st US Circuit Court of Appeals in Boston said Friday that the airline alliance harmed consumers by reducing their choices for flights from airports in the Northeast US including New York City.
"Presented with an arrangement that had many of the essential attributes of an agreement between two powerful competitors sharing revenues and divvying up highly concentrated markets, the district court conducted ...
 &nbsp;

Legal

JBLU

'American-JetBlue Alliance Breakup Upheld By Appeals Court' - Bloomberg Law

Raymond James analyst Aaron Kessler maintains Pinterest (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PINS#NYSE">PINS</a>) with a Outperform and lowers the price target from $40 to $34.

PINS

Raymond James Maintains Outperform on Pinterest, Lowers Price Target to $34

Barclays analyst Benjamin Budish maintains Marex Group (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MRX#NASDAQ">MRX</a>) with a Overweight and raises the price target from $30 to $32.

Barclays Maintains Overweight on Marex Group, Raises Price Target to $32

Analysts' ratings for APA (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/APA#NASDAQ">APA</a>) over the last quarter vary from bullish to bearish, as provided by 20 analysts.
Summarizing their recent assessments, the table below illustrates the evolving sentiments in the past 30 days and compares them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">3</td>
<td align="right">4</td>
<td align="right">11</td>
<td align="right">1</td>
<td align="right">1</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">7</td>
<td align="right">1</td>
<td align="right">1</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">0</td>
<td align="right">2</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
In the assessment of 12-month price targets, analysts unveil insights for APA, presenting an average target of $35.6, a high estimate of $52.00, and a low estimate of $26.00. A negative shift in sentiment is evident as analysts have decreased the average price target by 9.07%. 
<img src="https://www.benzinga.com/files/images/story/2024/1731089448_0.png" alt="price target chart" />
<h2>Analyzing Analyst Ratings: A Detailed Breakdown</h2>
In examining recent analyst actions, we gain insights into how financial experts perceive APA. The following summary outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Neal Dingmann</td>
<td>Truist Securities</td>
<td>Lowers</td>
<td>Buy</td>
<td>$33.00</td>
<td>$36.00</td>
</tr>
<tr>
<td>Biju Perincheril</td>
<td>Susquehanna</td>
<td>Lowers</td>
<td>Positive</td>
<td>$48.00</td>
<td>$52.00</td>
</tr>
<tr>
<td>Mark Lear</td>
<td>Piper Sandler</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$28.00</td>
<td>$29.00</td>
</tr>
<tr>
<td>Paul Cheng</td>
<td>Scotiabank</td>
<td>Lowers</td>
<td>Sector Perform</td>
<td>$27.00</td>
<td>$30.00</td>
</tr>
<tr>
<td>Neal Dingmann</td>
<td>Truist Securities</td>
<td>Raises</td>
<td>Buy</td>
<td>$36.00</td>
<td>$34.00</td>
</tr>
<tr>
<td>Neil Mehta</td>
<td>Goldman Sachs</td>
<td>Lowers</td>
<td>Sell</td>
<td>$26.00</td>
<td>$30.00</td>
</tr>
<tr>
<td>Betty Jiang</td>
<td>Barclays</td>
<td>Lowers</td>
<td>Equal-Weight</td>
<td>$30.00</td>
<td>$35.00</td>
</tr>
<tr>
<td>Roger Read</td>
<td>Wells Fargo</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$47.00</td>
<td>$49.00</td>
</tr>
<tr>
<td>Stephen Richardson</td>
<td>Evercore ISI Group</td>
<td>Lowers</td>
<td>In-Line</td>
<td>$33.00</td>
<td>$39.00</td>
</tr>
<tr>
<td>Neal Dingmann</td>
<td>Truist Securities</td>
<td>Lowers</td>
<td>Buy</td>
<td>$34.00</td>
<td>$46.00</td>
</tr>
<tr>
<td>Josh Silverstein</td>
<td>UBS</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$29.00</td>
<td>$35.00</td>
</tr>
<tr>
<td>Scott Hanold</td>
<td>RBC Capital</td>
<td>Maintains</td>
<td>Sector Perform</td>
<td>$41.00</td>
<td>$41.00</td>
</tr>
<tr>
<td>William Janela</td>
<td>Mizuho</td>
<td>Lowers</td>
<td>Underperform</td>
<td>$28.00</td>
<td>$35.00</td>
</tr>
<tr>
<td>Arun Jayaram</td>
<td>JP Morgan</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$27.00</td>
<td>$36.00</td>
</tr>
<tr>
<td>Stephen Richardson</td>
<td>Evercore ISI Group</td>
<td>Maintains</td>
<td>In-Line</td>
<td>$39.00</td>
<td>$39.00</td>
</tr>
<tr>
<td>Betty Jiang</td>
<td>Barclays</td>
<td>Maintains</td>
<td>Equal-Weight</td>
<td>$35.00</td>
<td>$35.00</td>
</tr>
<tr>
<td>Scott Hanold</td>
<td>RBC Capital</td>
<td>Maintains</td>
<td>Sector Perform</td>
<td>$41.00</td>
<td>$41.00</td>
</tr>
<tr>
<td>Biju Perincheril</td>
<td>Susquehanna</td>
<td>Lowers</td>
<td>Positive</td>
<td>$52.00</td>
<td>$57.00</td>
</tr>
<tr>
<td>Mark Lear</td>
<td>Piper Sandler</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$29.00</td>
<td>$34.00</td>
</tr>
<tr>
<td>Roger Read</td>
<td>Wells Fargo</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$49.00</td>
<td>$50.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: In response to dynamic market conditions and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their reaction to recent developments related to APA. This insight gives a snapshot of analysts' perspectives on the current state of the company.</li>
<li>Rating: Offering insights into predictions, analysts assign qualitative values, from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of APA compared to the broader market.</li>
<li>Price Targets: Understanding forecasts, analysts offer estimates for APA's future value. Examining the current and prior targets provides insight into analysts' changing expectations.</li>
</ul>
To gain a panoramic view of APA's market performance, explore these analyst evaluations alongside essential financial indicators. Stay informed and make judicious decisions using our Ratings Table.
<a href="https://www.benzinga.com/quote/APA/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on APA analyst ratings.</a>
<h2>About APA</h2>
Based in Houston, APA is an independent exploration and production company. It operates primarily in the US, Egypt, the North Sea, and Suriname. At year-end 2023, proved reserves totaled 807 million barrels of oil equivalent, with net reported production of 405 thousand boe/day that year (64% of which was oil and natural gas liquids, with the remainder natural gas).
<h3>Financial Milestones: APA's Journey</h3>
Market Capitalization Analysis: The company exhibits a lower market capitalization profile, positioning itself below industry averages. This suggests a smaller scale relative to peers.
Positive Revenue Trend: Examining APA's financials over 3 months reveals a positive narrative. The company achieved a noteworthy revenue growth rate of 41.59% as of 30 June, 2024, showcasing a substantial increase in top-line earnings. As compared to its peers, the company achieved a growth rate higher than the average among peers in Energy sector.
Net Margin: APA's net margin surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive 21.27% net margin, the company effectively manages costs and achieves strong profitability.
Return on Equity (ROE): APA's financial strength is reflected in its exceptional ROE, which exceeds industry averages. With a remarkable ROE of 13.47%, the company showcases efficient use of equity capital and strong financial health.
Return on Assets (ROA): APA's ROA stands out, surpassing industry averages. With an impressive ROA of 3.08%, the company demonstrates effective utilization of assets and strong financial performance.
Debt Management: APA's debt-to-equity ratio surpasses industry norms, standing at 1.26. This suggests the company carries a substantial amount of debt, posing potential financial challenges.
<h2>How Are Analyst Ratings Determined?</h2>
Benzinga tracks 150 analyst firms and reports on their stock expectations. Analysts typically arrive at their conclusions by predicting how much money a company will make in the future, usually the upcoming five years, and how risky or predictable that company's revenue streams are.
Analysts attend company conference calls and meetings, research company financial statements, and communicate with insiders to publish their ratings on stocks. Analysts typically rate each stock once per quarter or whenever the company has a major update.
In addition to their assessments, some analysts extend their insights by offering predictions for key metrics such as earnings, revenue, and growth estimates. This supplementary information provides further guidance for traders. It is crucial to recognize that, despite their specialization, analysts are human and can only provide forecasts based on their beliefs.
Which Stocks Are Analysts Recommending Now?
Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;utm_source=benzinga-insights">Click here to stay ahead of the market</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

A Glimpse Into The Expert Outlook On APA Through 20 Analysts

AAON (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AAON#NASDAQ">AAON</a>) underwent analysis by 4 analysts in the last quarter, revealing a spectrum of viewpoints from bullish to bearish.
The following table summarizes their recent ratings, shedding light on the changing sentiments within the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">1</td>
<td align="right">2</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
Providing deeper insights, analysts have established 12-month price targets, indicating an average target of $132.25, along with a high estimate of $150.00 and a low estimate of $111.00. Observing a 14.67% increase, the current average has risen from the previous average price target of $115.33. 
<img src="https://www.benzinga.com/files/images/story/2024/1731089431_0.png" alt="price target chart" />
<h2>Understanding Analyst Ratings: A Comprehensive Breakdown</h2>
An in-depth analysis of recent analyst actions unveils how financial experts perceive AAON. The following summary outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Brent Thielman</td>
<td>DA Davidson</td>
<td>Raises</td>
<td>Buy</td>
<td>$150.00</td>
<td>$102.00</td>
</tr>
<tr>
<td>Timothy Wojs</td>
<td>Baird</td>
<td>Raises</td>
<td>Outperform</td>
<td>$138.00</td>
<td>$130.00</td>
</tr>
<tr>
<td>Timothy Wojs</td>
<td>Baird</td>
<td>Raises</td>
<td>Outperform</td>
<td>$130.00</td>
<td>$114.00</td>
</tr>
<tr>
<td>Julio Romero</td>
<td>Sidoti &amp; Co.</td>
<td>Announces</td>
<td>Neutral</td>
<td>$111.00</td>
<td>-</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts frequently update their recommendations based on evolving market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to AAON. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Offering a comprehensive view, analysts assess stocks qualitatively, spanning from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of AAON compared to the broader market.</li>
<li>Price Targets: Delving into movements, analysts provide estimates for the future value of AAON's stock. This analysis reveals shifts in analysts' expectations over time.</li>
</ul>
Capture valuable insights into AAON's market standing by understanding these analyst evaluations alongside pertinent financial indicators. Stay informed and make strategic decisions with our Ratings Table.
<a href="https://www.benzinga.com/quote/AAON/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on AAON analyst ratings.</a>
<h2>Delving into AAON's Background</h2>
AAON Inc is a manufacturer of air-conditioning and heating equipment. The products include rooftop units, chillers, packaged outdoor mechanical rooms, air-handling units, makeup air units, energy-recovery units, condensing units, geothermal heat pumps, and self-contained units and coils. AAON's products serve the commercial and industrial new construction and replacement markets, primarily in North America.
<h3>AAON: A Financial Overview</h3>
Market Capitalization: Indicating a reduced size compared to industry averages, the company's market capitalization poses unique challenges.
Revenue Growth: AAON's revenue growth over a period of 3 months has been noteworthy. As of 30 June, 2024, the company achieved a revenue growth rate of approximately 10.43%. This indicates a substantial increase in the company's top-line earnings. As compared to competitors, the company surpassed expectations with a growth rate higher than the average among peers in the Industrials sector.
Net Margin: AAON's net margin is impressive, surpassing industry averages. With a net margin of 16.66%, the company demonstrates strong profitability and effective cost management.
Return on Equity (ROE): AAON's ROE falls below industry averages, indicating challenges in efficiently using equity capital. With an ROE of 6.85%, the company may face hurdles in generating optimal returns for shareholders.
Return on Assets (ROA): The company's ROA is a standout performer, exceeding industry averages. With an impressive ROA of 5.32%, the company showcases effective utilization of assets.
Debt Management: AAON's debt-to-equity ratio is below the industry average. With a ratio of 0.14, the company relies less on debt financing, maintaining a healthier balance between debt and equity, which can be viewed positively by investors.
<h2>How Are Analyst Ratings Determined?</h2>
Within the domain of banking and financial systems, analysts specialize in reporting for specific stocks or defined sectors. Their work involves attending company conference calls and meetings, researching company financial statements, and communicating with insiders to publish "analyst ratings" for stocks. Analysts typically assess and rate each stock once per quarter.
Some analysts will also offer forecasts for metrics like growth estimates, earnings, and revenue to provide further guidance on stocks. Investors who use analyst ratings should note that this specialized advice comes from humans and may be subject to error.
Breaking: Wall Street's Next Big Mover
Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;utm_source=benzinga-insights">Click here for urgent details</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

AAON

Peeling Back The Layers: Exploring AAON Through Analyst Insights

RBC Capital analyst Nik Modi maintains Hershey (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HSY#NYSE">HSY</a>) with a Sector Perform and lowers the price target from $205 to $183.

RBC Capital Maintains Sector Perform on Hershey, Lowers Price Target to $183

Barclays analyst Balaji Prasad maintains Ligand Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LGND#NASDAQ">LGND</a>) with a Overweight and raises the price target from $125 to $150.

LGND

Barclays Maintains Overweight on Ligand Pharmaceuticals, Raises Price Target to $150

33 analysts have expressed a variety of opinions on Enphase Energy (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ENPH#NASDAQ">ENPH</a>) over the past quarter, offering a diverse set of opinions from bullish to bearish.
The table below summarizes their recent ratings, showcasing the evolving sentiments within the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">5</td>
<td align="right">6</td>
<td align="right">17</td>
<td align="right">3</td>
<td align="right">2</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">5</td>
<td align="right">6</td>
<td align="right">13</td>
<td align="right">3</td>
<td align="right">1</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">1</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
Providing deeper insights, analysts have established 12-month price targets, indicating an average target of $100.45, along with a high estimate of $145.00 and a low estimate of $61.00. Observing a downward trend, the current average is 16.42% lower than the prior average price target of $120.19. 
<img src="https://www.benzinga.com/files/images/story/2024/1731089390_0.png" alt="price target chart" />
<h2>Exploring Analyst Ratings: An In-Depth Overview</h2>
An in-depth analysis of recent analyst actions unveils how financial experts perceive Enphase Energy. The following summary outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Daniel Yang</td>
<td>HSBC</td>
<td>Lowers</td>
<td>Hold</td>
<td>$81.00</td>
<td>$154.00</td>
</tr>
<tr>
<td>Sean Milligan</td>
<td>Jefferies</td>
<td>Lowers</td>
<td>Underperform</td>
<td>$61.00</td>
<td>$93.00</td>
</tr>
<tr>
<td>Julien Dumoulin-Smith</td>
<td>B of A Securities</td>
<td>Lowers</td>
<td>Underperform</td>
<td>$62.00</td>
<td>$72.00</td>
</tr>
<tr>
<td>Tom Curran</td>
<td>Seaport Global</td>
<td>Lowers</td>
<td>Buy</td>
<td>$129.00</td>
<td>$144.00</td>
</tr>
<tr>
<td>Gus Richard</td>
<td>Northland Capital Markets</td>
<td>Lowers</td>
<td>Outperform</td>
<td>$110.00</td>
<td>$150.00</td>
</tr>
<tr>
<td>Biju Perincheril</td>
<td>Susquehanna</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$85.00</td>
<td>$104.00</td>
</tr>
<tr>
<td>Vikram Bagri</td>
<td>Citigroup</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$88.00</td>
<td>$99.00</td>
</tr>
<tr>
<td>Chris Dendrinos</td>
<td>RBC Capital</td>
<td>Lowers</td>
<td>Sector Perform</td>
<td>$85.00</td>
<td>$100.00</td>
</tr>
<tr>
<td>Christine Cho</td>
<td>Barclays</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$114.00</td>
<td>$129.00</td>
</tr>
<tr>
<td>Austin Moeller</td>
<td>Canaccord Genuity</td>
<td>Lowers</td>
<td>Hold</td>
<td>$95.00</td>
<td>$140.00</td>
</tr>
<tr>
<td>Mark Strouse</td>
<td>JP Morgan</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$120.00</td>
<td>$130.00</td>
</tr>
<tr>
<td>Philip Shen</td>
<td>Roth MKM</td>
<td>Lowers</td>
<td>Buy</td>
<td>$100.00</td>
<td>$130.00</td>
</tr>
<tr>
<td>Brian Lee</td>
<td>Goldman Sachs</td>
<td>Lowers</td>
<td>Buy</td>
<td>$145.00</td>
<td>$170.00</td>
</tr>
<tr>
<td>James West</td>
<td>Evercore ISI Group</td>
<td>Lowers</td>
<td>Outperform</td>
<td>$125.00</td>
<td>$133.00</td>
</tr>
<tr>
<td>Pavel Molchanov</td>
<td>Raymond James</td>
<td>Lowers</td>
<td>Outperform</td>
<td>$130.00</td>
<td>$140.00</td>
</tr>
<tr>
<td>Eric Stine</td>
<td>Craig-Hallum</td>
<td>Lowers</td>
<td>Buy</td>
<td>$123.00</td>
<td>$153.00</td>
</tr>
<tr>
<td>Kashy Harrison</td>
<td>Piper Sandler</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$85.00</td>
<td>$105.00</td>
</tr>
<tr>
<td>Colin Rusch</td>
<td>Oppenheimer</td>
<td>Lowers</td>
<td>Outperform</td>
<td>$101.00</td>
<td>$134.00</td>
</tr>
<tr>
<td>Joseph Osha</td>
<td>Guggenheim</td>
<td>Announces</td>
<td>Sell</td>
<td>$73.00</td>
<td>-</td>
</tr>
<tr>
<td>Andrew Percoco</td>
<td>Morgan Stanley</td>
<td>Lowers</td>
<td>Equal-Weight</td>
<td>$93.00</td>
<td>$102.00</td>
</tr>
<tr>
<td>Sean Milligan</td>
<td>Janney Montgomery Scott</td>
<td>Announces</td>
<td>Neutral</td>
<td>$83.00</td>
<td>-</td>
</tr>
<tr>
<td>Vikram Bagri</td>
<td>Citigroup</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$99.00</td>
<td>$114.00</td>
</tr>
<tr>
<td>Kashy Harrison</td>
<td>Piper Sandler</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$105.00</td>
<td>$115.00</td>
</tr>
<tr>
<td>Biju Perincheril</td>
<td>Susquehanna</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$104.00</td>
<td>$147.00</td>
</tr>
<tr>
<td>Jordan Levy</td>
<td>Truist Securities</td>
<td>Lowers</td>
<td>Buy</td>
<td>$110.00</td>
<td>$130.00</td>
</tr>
<tr>
<td>Chris Dendrinos</td>
<td>RBC Capital</td>
<td>Lowers</td>
<td>Sector Perform</td>
<td>$100.00</td>
<td>$125.00</td>
</tr>
<tr>
<td>Ameet Thakkar</td>
<td>BMO Capital</td>
<td>Lowers</td>
<td>Market Perform</td>
<td>$104.00</td>
<td>$114.00</td>
</tr>
<tr>
<td>Julien Dumoulin-Smith</td>
<td>B of A Securities</td>
<td>Raises</td>
<td>Underperform</td>
<td>$84.00</td>
<td>$82.00</td>
</tr>
<tr>
<td>Andrew Percoco</td>
<td>Morgan Stanley</td>
<td>Raises</td>
<td>Equal-Weight</td>
<td>$102.00</td>
<td>$100.00</td>
</tr>
<tr>
<td>Joseph Osha</td>
<td>Guggenheim</td>
<td>Lowers</td>
<td>Sell</td>
<td>$90.00</td>
<td>$93.00</td>
</tr>
<tr>
<td>Ameet Thakkar</td>
<td>BMO Capital</td>
<td>Lowers</td>
<td>Market Perform</td>
<td>$114.00</td>
<td>$115.00</td>
</tr>
<tr>
<td>Dushyant Ailani</td>
<td>Jefferies</td>
<td>Raises</td>
<td>Hold</td>
<td>$115.00</td>
<td>$111.00</td>
</tr>
<tr>
<td>Andrew Percoco</td>
<td>Morgan Stanley</td>
<td>Raises</td>
<td>Equal-Weight</td>
<td>$100.00</td>
<td>$98.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts frequently update their recommendations based on evolving market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to Enphase Energy. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Providing a comprehensive analysis, analysts offer qualitative assessments, ranging from 'Outperform' to 'Underperform'. These ratings reflect expectations for the relative performance of Enphase Energy compared to the broader market.</li>
<li>Price Targets: Analysts navigate through adjustments in price targets, providing estimates for Enphase Energy's future value. Comparing current and prior targets offers insights into analysts' evolving expectations.</li>
</ul>
Assessing these analyst evaluations alongside crucial financial indicators can provide a comprehensive overview of Enphase Energy's market position. Stay informed and make well-judged decisions with the assistance of our Ratings Table.
<a href="https://www.benzinga.com/quote/ENPH/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on Enphase Energy analyst ratings.</a>
<h2>Delving into Enphase Energy's Background</h2>
Enphase Energy is a global energy technology company. The company delivers smart, easy-to-use solutions that manage solar generation, storage, and communication on one platform. The company's microinverter technology primarily serves the rooftop solar market and produces a fully integrated solar-plus-storage solution. Geographically, it derives a majority of revenue from the United States.
<h3>Unraveling the Financial Story of Enphase Energy</h3>
Market Capitalization: With restricted market capitalization, the company is positioned below industry averages. This reflects a smaller scale relative to peers.
Revenue Growth: Enphase Energy's revenue growth over a period of 3 months has faced challenges. As of 30 September, 2024, the company experienced a revenue decline of approximately -30.89%. This indicates a decrease in the company's top-line earnings. In comparison to its industry peers, the company trails behind with a growth rate lower than the average among peers in the Information Technology sector.
Net Margin: Enphase Energy's financial strength is reflected in its exceptional net margin, which exceeds industry averages. With a remarkable net margin of 12.02%, the company showcases strong profitability and effective cost management.
Return on Equity (ROE): Enphase Energy's ROE stands out, surpassing industry averages. With an impressive ROE of 5.04%, the company demonstrates effective use of equity capital and strong financial performance.
Return on Assets (ROA): Enphase Energy's ROA excels beyond industry benchmarks, reaching 1.42%. This signifies efficient management of assets and strong financial health.
Debt Management: Enphase Energy's debt-to-equity ratio surpasses industry norms, standing at 1.4. This suggests the company carries a substantial amount of debt, posing potential financial challenges.
<h2>The Basics of Analyst Ratings</h2>
Benzinga tracks 150 analyst firms and reports on their stock expectations. Analysts typically arrive at their conclusions by predicting how much money a company will make in the future, usually the upcoming five years, and how risky or predictable that company's revenue streams are.
Analysts attend company conference calls and meetings, research company financial statements, and communicate with insiders to publish their ratings on stocks. Analysts typically rate each stock once per quarter or whenever the company has a major update.
Some analysts will also offer forecasts for metrics like growth estimates, earnings, and revenue to provide further guidance on stocks. Investors who use analyst ratings should note that this specialized advice comes from humans and may be subject to error.
Which Stocks Are Analysts Recommending Now?
Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;utm_source=benzinga-insights">Click here to stay ahead of the market</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

ENPH

Deep Dive Into Enphase Energy Stock: Analyst Perspectives (33 Ratings)

In the latest quarter, 8 analysts provided ratings for Five9 (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FIVN#NASDAQ">FIVN</a>), showcasing a mix of bullish and bearish perspectives.
Summarizing their recent assessments, the table below illustrates the evolving sentiments in the past 30 days and compares them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">3</td>
<td align="right">3</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">2</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
Insights from analysts' 12-month price targets are revealed, presenting an average target of $48.88, a high estimate of $65.00, and a low estimate of $37.00. A 0.49% drop is evident in the current average compared to the previous average price target of $49.12. 
<img src="https://www.benzinga.com/files/images/story/2024/1731089379_0.png" alt="price target chart" />
<h2>Deciphering Analyst Ratings: An In-Depth Analysis</h2>
An in-depth analysis of recent analyst actions unveils how financial experts perceive Five9. The following summary outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Gil Luria</td>
<td>DA Davidson</td>
<td>Raises</td>
<td>Neutral</td>
<td>$45.00</td>
<td>$40.00</td>
</tr>
<tr>
<td>James Fish</td>
<td>Piper Sandler</td>
<td>Raises</td>
<td>Overweight</td>
<td>$46.00</td>
<td>$35.00</td>
</tr>
<tr>
<td>Scott Berg</td>
<td>Needham</td>
<td>Maintains</td>
<td>Buy</td>
<td>$48.00</td>
<td>$48.00</td>
</tr>
<tr>
<td>Michael Turrin</td>
<td>Wells Fargo</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$55.00</td>
<td>$65.00</td>
</tr>
<tr>
<td>Lauren Lieberman</td>
<td>Morgan Stanley</td>
<td>Lowers</td>
<td>Equal-Weight</td>
<td>$37.00</td>
<td>$45.00</td>
</tr>
<tr>
<td>Terry Tillman</td>
<td>Truist Securities</td>
<td>Maintains</td>
<td>Buy</td>
<td>$65.00</td>
<td>$65.00</td>
</tr>
<tr>
<td>James Fish</td>
<td>Piper Sandler</td>
<td>Maintains</td>
<td>Overweight</td>
<td>$47.00</td>
<td>$47.00</td>
</tr>
<tr>
<td>Scott Berg</td>
<td>Needham</td>
<td>Maintains</td>
<td>Buy</td>
<td>$48.00</td>
<td>$48.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts respond to changes in market conditions and company performance, frequently updating their recommendations. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to Five9. This information offers a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Offering a comprehensive view, analysts assess stocks qualitatively, spanning from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of Five9 compared to the broader market.</li>
<li>Price Targets: Analysts set price targets as an estimate of a stock's future value. Comparing the current and prior price targets provides insight into how analysts' expectations have changed over time. This information can be valuable for investors seeking to understand consensus views on the stock's potential future performance.</li>
</ul>
Considering these analyst evaluations in conjunction with other financial indicators can offer a comprehensive understanding of Five9's market position. Stay informed and make well-informed decisions with our Ratings Table.
<a href="https://www.benzinga.com/quote/FIVN/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on Five9 analyst ratings.</a>
<h2>All You Need to Know About Five9</h2>
Five9 offers cloud-native contact center software enabling digital customer service, sales, and marketing engagement. The company's Virtual Contact Center platform combines core telephony functionality, omnichannel engagement, and various modules into a unified cloud contact-center-as-a-service, or CCaaS, platform. Five9's modules include digital self-service, agent assist technology, workflow automation, as well as workforce optimization solutions that optimize call center efficiency, and manage interaction quality and agent performance.
<h3>Financial Milestones: Five9's Journey</h3>
Market Capitalization Analysis: Positioned below industry benchmarks, the company's market capitalization faces constraints in size. This could be influenced by factors such as growth expectations or operational capacity.
Revenue Growth: Five9's remarkable performance in 3 months is evident. As of 30 June, 2024, the company achieved an impressive revenue growth rate of 13.1%. This signifies a substantial increase in the company's top-line earnings. When compared to others in the Information Technology sector, the company faces challenges, achieving a growth rate lower than the average among peers.
Net Margin: Five9's net margin excels beyond industry benchmarks, reaching -5.08%. This signifies efficient cost management and strong financial health.
Return on Equity (ROE): The company's ROE is a standout performer, exceeding industry averages. With an impressive ROE of -2.54%, the company showcases effective utilization of equity capital.
Return on Assets (ROA): Five9's ROA surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive -0.68% ROA, the company effectively utilizes its assets for optimal returns.
Debt Management: The company faces challenges in debt management with a debt-to-equity ratio higher than the industry average. With a ratio of 2.3, caution is advised due to increased financial risk.
<h2>The Significance of Analyst Ratings Explained</h2>
Analyst ratings serve as essential indicators of stock performance, provided by experts in banking and financial systems. These specialists diligently analyze company financial statements, participate in conference calls, and engage with insiders to generate quarterly ratings for individual stocks.
Some analysts publish their predictions for metrics such as growth estimates, earnings, and revenue to provide additional guidance with their ratings. When using analyst ratings, it is important to keep in mind that stock and sector analysts are also human and are only offering their opinions to investors.
If you want to keep track of which analysts are outperforming others, you can view updated analyst ratings along withanalyst success scores in <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a>.
Which Stocks Are Analysts Recommending Now?
Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;utm_source=benzinga-insights">Click here to stay ahead of the market</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

FIVN

Cracking The Code: Understanding Analyst Reviews For Five9

Across the recent three months, 8 analysts have shared their insights on Gulfport Energy (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GPOR#NYSE">GPOR</a>), expressing a variety of opinions spanning from bullish to bearish.
The following table summarizes their recent ratings, shedding light on the changing sentiments within the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">3</td>
<td align="right">2</td>
<td align="right">3</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
Analysts provide deeper insights through their assessments of 12-month price targets, revealing an average target of $180.62, a high estimate of $203.00, and a low estimate of $162.00. Observing a 0.13% increase, the current average has risen from the previous average price target of $180.38. 
<img src="https://www.benzinga.com/files/images/story/2024/1731089367_0.png" alt="price target chart" />
<h2>Breaking Down Analyst Ratings: A Detailed Examination</h2>
The analysis of recent analyst actions sheds light on the perception of Gulfport Energy by financial experts. The following summary presents key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Bertrand Donnes</td>
<td>Truist Securities</td>
<td>Raises</td>
<td>Buy</td>
<td>$203.00</td>
<td>$190.00</td>
</tr>
<tr>
<td>Nitin Kumar</td>
<td>Mizuho</td>
<td>Raises</td>
<td>Neutral</td>
<td>$174.00</td>
<td>$173.00</td>
</tr>
<tr>
<td>Zach Parham</td>
<td>JP Morgan</td>
<td>Raises</td>
<td>Overweight</td>
<td>$175.00</td>
<td>$162.00</td>
</tr>
<tr>
<td>Stephen Richardson</td>
<td>Evercore ISI Group</td>
<td>Maintains</td>
<td>In-Line</td>
<td>$170.00</td>
<td>$170.00</td>
</tr>
<tr>
<td>Bertrand Donnes</td>
<td>Truist Securities</td>
<td>Lowers</td>
<td>Buy</td>
<td>$190.00</td>
<td>$198.00</td>
</tr>
<tr>
<td>Nitin Kumar</td>
<td>Mizuho</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$173.00</td>
<td>$178.00</td>
</tr>
<tr>
<td>Zach Parham</td>
<td>JP Morgan</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$162.00</td>
<td>$178.00</td>
</tr>
<tr>
<td>Bertrand Donnes</td>
<td>Truist Securities</td>
<td>Raises</td>
<td>Buy</td>
<td>$198.00</td>
<td>$194.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts respond to changes in market conditions and company performance, frequently updating their recommendations. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to Gulfport Energy. This information offers a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Gaining insights, analysts provide qualitative assessments, ranging from 'Outperform' to 'Underperform'. These ratings reflect expectations for the relative performance of Gulfport Energy compared to the broader market.</li>
<li>Price Targets: Understanding forecasts, analysts offer estimates for Gulfport Energy's future value. Examining the current and prior targets provides insight into analysts' changing expectations.</li>
</ul>
Assessing these analyst evaluations alongside crucial financial indicators can provide a comprehensive overview of Gulfport Energy's market position. Stay informed and make well-judged decisions with the assistance of our Ratings Table.
<a href="https://www.benzinga.com/quote/GPOR/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on Gulfport Energy analyst ratings.</a>
<h2>Get to Know Gulfport Energy Better</h2>
Gulfport Energy Corp is an independent natural gas-weighted exploration and production company focused on the exploration, acquisition and production of natural gas, crude oil and NGL in the United States. It operates through Utica Shale and Scoop properties. The Utica Shale is located in the Appalachian Basin of the United States and Canada. The Scoop (South Central Oklahoma Oil Province) play of Oklahoma is located in the southeast portion of the prolific Anadarko Basin.
<h3>Financial Insights: Gulfport Energy</h3>
Market Capitalization Analysis: Falling below industry benchmarks, the company's market capitalization reflects a reduced size compared to peers. This positioning may be influenced by factors such as growth expectations or operational capacity.
Decline in Revenue: Over the 3 months period, Gulfport Energy faced challenges, resulting in a decline of approximately -4.97% in revenue growth as of 30 September, 2024. This signifies a reduction in the company's top-line earnings. As compared to its peers, the revenue growth lags behind its industry peers. The company achieved a growth rate lower than the average among peers in Energy sector.
Net Margin: Gulfport Energy's net margin is below industry standards, pointing towards difficulties in achieving strong profitability. With a net margin of -6.97%, the company may encounter challenges in effective cost control.
Return on Equity (ROE): Gulfport Energy's ROE is below industry standards, pointing towards difficulties in efficiently utilizing equity capital. With an ROE of -0.72%, the company may encounter challenges in delivering satisfactory returns for shareholders.
Return on Assets (ROA): The company's ROA is below industry benchmarks, signaling potential difficulties in efficiently utilizing assets. With an ROA of -0.47%, the company may need to address challenges in generating satisfactory returns from its assets.
Debt Management: Gulfport Energy's debt-to-equity ratio is below the industry average at 0.34, reflecting a lower dependency on debt financing and a more conservative financial approach.
<h2>What Are Analyst Ratings?</h2>
Benzinga tracks 150 analyst firms and reports on their stock expectations. Analysts typically arrive at their conclusions by predicting how much money a company will make in the future, usually the upcoming five years, and how risky or predictable that company's revenue streams are.
Analysts attend company conference calls and meetings, research company financial statements, and communicate with insiders to publish their ratings on stocks. Analysts typically rate each stock once per quarter or whenever the company has a major update.
Some analysts also offer predictions for helpful metrics such as earnings, revenue, and growth estimates to provide further guidance as to what to do with certain tickers. It is important to keep in mind that while stock and sector analysts are specialists, they are also human and can only forecast their beliefs to traders.
Breaking: Wall Street's Next Big Mover
Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;utm_source=benzinga-insights">Click here for urgent details</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

GPOR

Deep Dive Into Gulfport Energy Stock: Analyst Perspectives (8 Ratings)

Tesla, Inc.&#8217;s (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TSLA#NASDAQ">TSLA</a>) October sales in China took a hit as exports from its Shanghai plant surged.
Per a <a target="_blank" href="https://cnevpost.com/2024/11/08/tesla-sells-40485-cars-china-oct-2024/" rel="noreferrer noopener">report</a> by CnEV Post, the company sold 68,280 vehicles in total, with 27,795 units shipped overseas, according to data from the China Passenger Car Association (CPCA). This left Tesla with just 40,485 vehicles sold within China, marking its weakest month since April.
However, TSLA stock is on the rise, fueled by a post-election rally following Donald Trump&#8217;s victory in the 2024 presidential race.
The boost in Tesla&#8217;s stock may be tied to Elon Musk&#8217;s backing of Trump, which seemingly paid off with a <a target="_blank" href="https://www.benzinga.com/markets/equities/24/11/41813356/elon-musks-net-worth-soars-by-26-5-billion-in-single-day-after-tesla-stock-surges-post-trump-vic" rel="noreferrer noopener">massive surge in his wealth.</a>
In addition, B of A Securities analyst John Murphy has raised Tesla&#8217;s price forecast from $265 to $350, <a target="_blank" href="https://www.benzinga.com/quote/TSLA/analyst-ratings" rel="noreferrer noopener">maintaining a Buy rating on the stock.</a>
Also Read: <a target="_blank" href="https://www.benzinga.com/markets/equities/24/11/41757075/tesla-lures-chinese-buyers-with-exclusive-giga-shanghai-tour-giveaway-to-boost-sales-report" rel="noreferrer noopener">Tesla Lures Chinese Buyers With Exclusive Giga Shanghai Tour Giveaway to Boost Sales: Report</a>
Tesla&#8217;s October sales in China were up 41.43% from 28,626 vehicles sold last year, but down 43.93% from 72,200 units in September, CnEV Post added.
For the year-to-date period from January to October, Tesla has sold 500,685 vehicles in China, crossing the 500,000 mark. This represents an 8.29% increase compared to the same period last year.
Earlier this week, Tesla was in the headlines for luring its customers with a new incentive to promote car purchases and capitalize on&nbsp;<a target="_blank" href="https://www.benzinga.com/news/24/11/41738613/elon-musk-rejects-rumors-of-a-tesla-phone-but-says-the-ev-giant-will-have-to-make-one-if-this-happen" rel="noreferrer noopener">China&#8217;s auto consumption stimulus.</a> The EV giant is offering Chinese customers the chance to win a tour of its Giga Shanghai factory.
Tesla China&#8217;s Gigafactory Shanghai is the EV giant&#8217;s largest by production volume, with an estimated annual output exceeding 950,000 vehicles, according to the third quarter 2024 Update Letter, Teslarati <a target="_blank" href="https://www.teslarati.com/tesla-china-giga-shanghai-tour-incentive/" rel="noreferrer noopener">reported</a>. Giga Shanghai manufactures the Model 3 and Model Y for both the domestic Chinese market and international markets.
Price Action: TSLA shares are trading higher by 7.05% to $317.83 at the last check on Friday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/tech/24/11/41841181/tesla-opens-cybertruck-lease-option-for-as-low-as-999-per-month" target="_blank" rel="noreferrer noopener">Tesla Opens Cybertruck Lease Option For As Low As $999 Per month</a></li>
</ul>
Photo via Shutterstock

Equities

Markets

Tech

TSLA

Tesla's China Sales Plunge to 6-Month Low In October, Exports Rise

Whales with a lot of money to spend have taken a noticeably bearish stance on KLA.
Looking at options history for KLA (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/KLAC#NASDAQ">KLAC</a>) we detected 9 trades.
If we consider the specifics of each trade, it is accurate to state that 22% of the investors opened trades with bullish expectations and 66% with bearish.
From the overall spotted trades, 6 are puts, for a total amount of $265,347 and 3, calls, for a total amount of $107,828.
<h3>Expected Price Movements</h3>
Taking into account the Volume and Open Interest on these contracts, it appears that whales have been targeting a price range from $640.0 to $800.0 for KLA over the last 3 months. 
<h3>Insights into Volume &amp; Open Interest</h3>
Assessing the volume and open interest is a strategic step in options trading. These metrics shed light on the liquidity and investor interest in KLA's options at specified strike prices. The forthcoming data visualizes the fluctuation in volume and open interest for both calls and puts, linked to KLA's substantial trades, within a strike price spectrum from $640.0 to $800.0 over the preceding 30 days.
<h3>KLA Call and Put Volume: 30-Day Overview</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1731089321_0.png" alt="Options Call Chart" />
<h3>Noteworthy Options Activity:</h3>

<table>
<thead>
<tr>
<th>Symbol</th>
<th>PUT/CALL</th>
<th>Trade Type</th>
<th>Sentiment</th>
<th>Exp. Date</th>
<th>Ask</th>
<th>Bid</th>
<th>Price</th>
<th>Strike Price</th>
<th>Total Trade Price</th>
<th align="right">Open Interest</th>
<th align="right">Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>KLAC</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>03/21/25</td>
<td>$37.1</td>
<td>$37.0</td>
<td>$37.0</td>
<td>$640.00</td>
<td>$74.0K</td>
<td align="right">160</td>
<td align="right">16</td>
</tr>
<tr>
<td>KLAC</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>01/17/25</td>
<td>$20.9</td>
<td>$20.3</td>
<td>$20.9</td>
<td>$640.00</td>
<td>$43.8K</td>
<td align="right">368</td>
<td align="right">21</td>
</tr>
<tr>
<td>KLAC</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>01/17/25</td>
<td>$20.8</td>
<td>$20.7</td>
<td>$20.8</td>
<td>$640.00</td>
<td>$43.6K</td>
<td align="right">368</td>
<td align="right">21</td>
</tr>
<tr>
<td>KLAC</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>01/17/25</td>
<td>$20.6</td>
<td>$20.5</td>
<td>$20.6</td>
<td>$640.00</td>
<td>$43.2K</td>
<td align="right">368</td>
<td align="right">43</td>
</tr>
<tr>
<td>KLAC</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>01/17/25</td>
<td>$10.7</td>
<td>$9.6</td>
<td>$9.6</td>
<td>$800.00</td>
<td>$41.2K</td>
<td align="right">180</td>
<td align="right">3</td>
</tr>
</tbody>
</table>

<h3>About KLA</h3>
KLA is one of the largest semiconductor wafer fabrication equipment, or WFE, manufacturers in the world. It specializes in the market segment of semiconductor process control, wherein machines inspect semiconductor wafers during research and development and manufacturing for defects and verify precise measurements. In this section of the market, KLA holds a majority share. It also has a small exposure to the etch and deposition segments of the WFE market. It counts as top customers the largest chipmakers in the world, including TSMC and Samsung.
<h3>Where Is KLA Standing Right Now?</h3>
<ul>
<li>Currently trading with a volume of 472,616, the KLAC's price is up by 0.38%, now at $688.79. </li>
<li>RSI readings suggest the stock is currently may be approaching oversold.</li>
<li>Anticipated earnings release is in 76 days.</li>
</ul>
Unusual Options Activity Detected: Smart Money on the Move
Benzinga Edge's Unusual Options board spots potential market movers before they happen. See what positions big money is taking on your favorite stocks. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=Be8be9arja3be22bz20&amp;utm_source=benzinga-insights">Click here for access</a>.
Options trading presents higher risks and potential rewards. Astute traders manage these risks by continually educating themselves, adapting their strategies, monitoring multiple indicators, and keeping a close eye on market movements. Stay informed about the latest KLA options trades with real-time alerts from <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a>.

Options

KLAC

Market Whales and Their Recent Bets on KLAC Options

Raymond James analyst Brian Peterson maintains OneStream (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OS#NASDAQ">OS</a>) with a Outperform and raises the price target from $34 to $35.

Raymond James Maintains Outperform on OneStream, Raises Price Target to $35

Whales with a lot of money to spend have taken a noticeably bullish stance on Constellation Energy.
Looking at options history for Constellation Energy (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CEG#NASDAQ">CEG</a>) we detected 8 trades.
If we consider the specifics of each trade, it is accurate to state that 62% of the investors opened trades with bullish expectations and 25% with bearish.
From the overall spotted trades, 3 are puts, for a total amount of $227,440 and 5, calls, for a total amount of $478,841.
<h3>Projected Price Targets</h3>
Analyzing the Volume and Open Interest in these contracts, it seems that the big players have been eyeing a price window from $135.0 to $320.0 for Constellation Energy during the past quarter. 
<h3>Insights into Volume &amp; Open Interest</h3>
Looking at the volume and open interest is an insightful way to conduct due diligence on a stock.
This data can help you track the liquidity and interest for Constellation Energy's options for a given strike price.
Below, we can observe the evolution of the volume and open interest of calls and puts, respectively, for all of Constellation Energy's whale activity within a strike price range from $135.0 to $320.0 in the last 30 days. 
<h3>Constellation Energy Option Volume And Open Interest Over Last 30 Days</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1731089315_0.png" alt="Options Call Chart" />
<h3>Noteworthy Options Activity:</h3>

<table>
<thead>
<tr>
<th>Symbol</th>
<th>PUT/CALL</th>
<th>Trade Type</th>
<th>Sentiment</th>
<th>Exp. Date</th>
<th>Ask</th>
<th>Bid</th>
<th>Price</th>
<th>Strike Price</th>
<th>Total Trade Price</th>
<th align="right">Open Interest</th>
<th align="right">Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>CEG</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>01/17/25</td>
<td>$113.3</td>
<td>$109.6</td>
<td>$113.3</td>
<td>$135.00</td>
<td>$238.0K</td>
<td align="right">61</td>
<td align="right">21</td>
</tr>
<tr>
<td>CEG</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>01/17/25</td>
<td>$5.2</td>
<td>$4.9</td>
<td>$4.9</td>
<td>$210.00</td>
<td>$171.5K</td>
<td align="right">475</td>
<td align="right">351</td>
</tr>
<tr>
<td>CEG</td>
<td>CALL</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>12/13/24</td>
<td>$12.4</td>
<td>$10.6</td>
<td>$12.08</td>
<td>$245.00</td>
<td>$120.8K</td>
<td align="right">19</td>
<td align="right">101</td>
</tr>
<tr>
<td>CEG</td>
<td>CALL</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>01/16/26</td>
<td>$26.0</td>
<td>$26.0</td>
<td>$26.0</td>
<td>$320.00</td>
<td>$52.0K</td>
<td align="right">38</td>
<td align="right">20</td>
</tr>
<tr>
<td>CEG</td>
<td>CALL</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>02/21/25</td>
<td>$42.1</td>
<td>$40.8</td>
<td>$40.8</td>
<td>$210.00</td>
<td>$40.8K</td>
<td align="right">71</td>
<td align="right">10</td>
</tr>
</tbody>
</table>

<h3>About Constellation Energy</h3>
Constellation Energy Corp offers energy solutions. It provides clean energy and sustainable solutions to homes, businesses, the public sector, community aggregations, and a range of wholesale customers (such as municipalities, cooperatives, and other strategics). The company offers comprehensive energy solutions and a variety of pricing options for electric, natural gas, and renewable energy products for companies of any size.
In light of the recent options history for Constellation Energy, it's now appropriate to focus on the company itself. We aim to explore its current performance.
<h3>Constellation Energy's Current Market Status</h3>
<ul>
<li>Trading volume stands at 1,921,888, with CEG's price down by -0.76%, positioned at $239.76.</li>
<li>RSI indicators show the stock to be is currently neutral between overbought and oversold.</li>
<li>Earnings announcement expected in 109 days.</li>
</ul>
<h3>What Analysts Are Saying About Constellation Energy</h3>
Over the past month, 5 industry analysts have shared their insights on this stock, proposing an average target price of $285.4.
Unusual Options Activity Detected: Smart Money on the Move
Benzinga Edge's Unusual Options board spots potential market movers before they happen. See what positions big money is taking on your favorite stocks. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=Be8be9arja3be22bz20&amp;utm_source=benzinga-insights">Click here for access</a>. 
&#x2A; Maintaining their stance, an analyst from Mizuho continues to hold a Neutral rating for Constellation Energy, targeting a price of $235. 
&#x2A; An analyst from Barclays has decided to maintain their Overweight rating on Constellation Energy, which currently sits at a price target of $270. 
&#x2A; An analyst from JP Morgan has revised its rating downward to Overweight, adjusting the price target to $342. 
&#x2A; Consistent in their evaluation, an analyst from Barclays keeps a Overweight rating on Constellation Energy with a target price of $282. 
&#x2A; An analyst from BMO Capital persists with their Outperform rating on Constellation Energy, maintaining a target price of $298. 
Options are a riskier asset compared to just trading the stock, but they have higher profit potential. Serious options traders manage this risk by educating themselves daily, scaling in and out of trades, following more than one indicator, and following the markets closely.
If you want to stay updated on the latest options trades for Constellation Energy, <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a> gives you real-time options trades alerts.

Unpacking the Latest Options Trading Trends in Constellation Energy

<a href="https://investorplace.com">InvestorPlace - Stock Market News, Stock Advice &amp; Trading Tips</a>
Petros Pharmaceuticals (NASDAQ:<a href="https://investorplace.com/stock-quotes/ptpi-stock-quote/">PTPI</a>) just reported results for the first quarter of 2024.<ul><li>Petros Pharmaceuticals reported earnings per share of -$1.69. This was below the analyst estimate for EPS of -$1.44.</li><li>The company reported revenue of $1.39 million.</li><li>This was 4.21% worse than the analyst estimate for revenue of $1.45 million.</li></ul><div>InvestorPlace Earnings is a project that leverages data from <a href="https://www.tradesmith.com">TradeSmith</a> to automate coverage of quarterly earnings reports. InvestorPlace Earnings distills key takeaways including earnings per share and revenue, as well as how a company stacks up to analyst estimates. These articles are published without human intervention, allowing us to inform our readers of the latest figures as quickly as possible. To report any concerns or inaccuracies, please contact us at <a href="mailto:editor@investorplace.com">editor@investorplace.com</a>.</div><h3>More From InvestorPlace</h3>
		<ul><li>
						<a href="https://investorplace.com/2023/10/no-1-ai-investment-might-be-this-company-youve-never-heard-of/?cid=MKT764787&amp;eid=MKT802110">The #1 AI Investment Might Be This Company You&rsquo;ve Never Heard Of</a>
					</li>
																<li>
						<a href="https://investorplace.com/2023/07/elon-musks-project-omega-stuns-silicon-valley-insiders/?cid=MKT738510&amp;eid=MKT766411">Musk&rsquo;s &ldquo;Project Omega&rdquo; May Be Set to Mint New Millionaires. Here&rsquo;s How to Get In.</a>
					</li>
																<li>
						<a href="https://investorplace.com/2024/04/legendary-investor-predicts-forget-a-i-this-technology-is-the-future/?cid=MKT794457&amp;eid=MKT802109">Legendary Investor Predicts: &ldquo;Forget A.I. THIS Technology Is the Future&rdquo;</a>
					</li>
									</ul><div>
			<div></div>
						<div></div>
					</div>
	The post <a href="https://investorplace.com/earning-results/2024/05/ptpi-stock-earnings-petros-pharmaceuticals-for-q1-of-2024/">PTPI Stock Earnings: Petros Pharmaceuticals Misses EPS, Misses Revenue for Q1 2024</a> appeared first on <a href="https://investorplace.com">InvestorPlace</a>.

PTPI Stock Earnings: Petros Pharmaceuticals Misses EPS, Misses Revenue for Q1 2024

Analyst Naz Rahman from Maxim Group maintained a Buy rating on Petros Pharmaceuticals (PTPI – Research Report) and keeping the price target at $4.0...

Buy Rating Affirmed for Petros Pharmaceuticals Amidst Strategic Shift to OTC Market and Positive Regulatory Prospects

Naz Rahman, an analyst from Maxim Group, maintained the Buy rating on Petros Pharmaceuticals (PTPI – Research Report). The associated price target ...

Buy Rating Justified for Petros Pharmaceuticals Amid AI Integration and Strategic OTC Expansion

<a href="https://investorplace.com">InvestorPlace - Stock Market News, Stock Advice &amp; Trading Tips</a>
Pre-market stock movers are worth checking out on Thursday as we break down all of the hottest stock market news this morning!



Moving stocks this morning are clinical trail updates, an earnings report, acquisition news and more.



Let&rsquo;s get into that news below!



<h2>Biggest Pre-Market Stock Movers: 10 Top Gainers</h2>



<ol><li>Neo-Concept (NASDAQ:<a href="https://investorplace.com/stock-quotes/nci-stock-quote/">NCI</a>) stock is rocketing more than 60% alongside heavy pre-market trading.</li>



<li>Sify Technologies Limited &ndash; Rights&nbsp;(NASDAQ:<a href="https://investorplace.com/stock-quotes/sifyr-stock-quote/">SIFYR</a>) shares are soaring over 29% <a href="https://www.nasdaq.com/articles/sify-technologies-sets-ads-rights-delisting-date">before their delisting next week</a>.</li>



<li>Longeveron (NASDAQ:<a href="https://investorplace.com/stock-quotes/lgvn-stock-quote/">LGVN</a>) stock is surging more than 28% <a href="https://investorplace.com/2024/06/why-is-longeveron-lgvn-stock-up-120-today/">with clinical trial news</a>.</li>



<li>Fangdd Network (NASDAQ:<a href="https://investorplace.com/stock-quotes/duo-stock-quote/">DUO</a>) shares are gaining over 24% with strong early morning trading.</li>



<li>Nxu (NASDAQ:<a href="https://investorplace.com/stock-quotes/nxu-stock-quote/">NXU</a>) stock is increasing more than 17% on heavy early morning trading.</li>



<li>Sequans Communications (NYSE:<a href="https://investorplace.com/stock-quotes/sqns-stock-quote/">SQNS</a>) shares are rising over 16% today.</li>



<li>Broadcom (NASDAQ:<a href="https://investorplace.com/stock-quotes/avgo-stock-quote/">AVGO</a>) stock is heading 13% higher on <a href="https://www.barrons.com/articles/broadcom-stock-split-earnings-0c75392f">Q2 earnings and stock split plans</a>.</li>



<li>Aethlon Medical (NASDAQ:<a href="https://investorplace.com/stock-quotes/aemd-stock-quote/">AEMD</a>) shares are climbing more than 11% without any clear news today.</li>



<li>CaliberCos (NASDAQ:<a href="https://investorplace.com/stock-quotes/cwd-stock-quote/">CWD</a>) stock is jumping over 11% this morning.</li>



<li>Roma Green Finance (NASDAQ:<a href="https://investorplace.com/stock-quotes/roma-stock-quote/">ROMA</a>) shares are up more than 10% </li>
</ol><h2>10 Top Losers</h2>



<ol><li>Assure (NASDAQ:<a href="https://investorplace.com/stock-quotes/ionm-stock-quote/">IONM</a>) stock is crashing over 52% after <a href="https://app.quotemedia.com/data/downloadFiling?webmasterId=90423&amp;ref=318390446&amp;type=PDF&amp;symbol=IONM&amp;cdn=e3ce016dbdad608e6e12f639f088590d&amp;companyName=Assure+Holdings+Corp.&amp;formType=425&amp;formDescription=Prospectuses+and+communications%2C+business+combinations&amp;dateFiled=2024-06-12">terminating a merger agreement</a>.</li>



<li>DDC Enterprise (NYSEMKT:<a href="https://investorplace.com/stock-quotes/ddc-stock-quote/">DDC</a>) shares are plummeting more than 28% after <a href="https://www.marketwatch.com/story/ddc-enterprise-shares-surge-after-purchase-of-omsom-2ae3de86?mod=markets">rallying yesterday on an acquisition</a>.</li>



<li>Cara Therapeutics (NASDAQ:<a href="https://investorplace.com/stock-quotes/cara-stock-quote/">CARA</a>) stock is diving over 20% alongside <a href="https://www.nasdaq.com/press-release/cara-therapeutics-announces-outcome-part-kourage-1-study-evaluating-oral">clinical trial results</a>.</li>



<li>Petros Pharma (NASDAQ:<a href="https://investorplace.com/stock-quotes/ptpi-stock-quote/">PTPI</a>) shares are tumbling more than 18% on Thursday morning.</li>



<li>PainReform (NASDAQ:<a href="https://investorplace.com/stock-quotes/prfx-stock-quote/">PRFX</a>) stock is taking an over 16% beating this morning.</li>



<li>J.Jill (NYSE:<a href="https://investorplace.com/stock-quotes/jill-stock-quote/">JILL</a>) shares are falling more than 16% after <a href="https://www.nasdaq.com/press-release/jjill-announces-pricing-public-offering-common-stock-2024-06-12">pricing a public offering</a>.</li>



<li>EpicQuest Education (NASDAQ:<a href="https://investorplace.com/stock-quotes/eeiq-stock-quote/">EEIQ</a>) stock is dropping over 16% this morning.</li>



<li>Expion360 (NASDAQ:<a href="https://investorplace.com/stock-quotes/xpon-stock-quote/">XPON</a>) shares are decreasing more than 14% today.</li>



<li>KWESST Micro Systems (NASDAQ:<a href="https://investorplace.com/stock-quotes/kwe-stock-quote/">KWE</a>) stock is declining over 12% as it <a href="https://investorplace.com/2024/06/why-is-kwesst-micro-systems-kwe-stock-up-121-today/">comes off a recent rally</a>.</li>



<li>VS Media (NASDAQ:<a href="https://investorplace.com/stock-quotes/vsme-stock-quote/">VSME</a>) shares close out our pre-market stock movers down more than 12%.</li>
</ol>On the date of publication, William White did not have (either directly or indirectly) any positions in the securities mentioned in this article. The opinions expressed in this article are those of the writer, subject to the&nbsp;InvestorPlace.com&nbsp;<a href="https://investorplace.com/corporate/investorplace-publishing-guidelines/" target="_blank">Publishing Guidelines</a>.
<h3>More From InvestorPlace</h3>
		<ul><li>
						<a href="https://investorplace.com/2023/10/no-1-ai-investment-might-be-this-company-youve-never-heard-of/?cid=MKT764787&amp;eid=MKT802110">The #1 AI Investment Might Be This Company You&rsquo;ve Never Heard Of</a>
					</li>
																<li>
						<a href="https://investorplace.com/2023/07/elon-musks-project-omega-stuns-silicon-valley-insiders/?cid=MKT738510&amp;eid=MKT766411">Musk&rsquo;s &ldquo;Project Omega&rdquo; May Be Set to Mint New Millionaires. Here&rsquo;s How to Get In.</a>
					</li>
																<li>
						<a href="https://investorplace.com/2024/04/legendary-investor-predicts-forget-a-i-this-technology-is-the-future/?cid=MKT794457&amp;eid=MKT802109">Legendary Investor Predicts: &ldquo;Forget A.I. THIS Technology Is the Future&rdquo;</a>
					</li>
									</ul><div>
			<div></div>
						<div></div>
					</div>
	The post <a href="https://investorplace.com/2024/06/todays-biggest-pre-market-stock-movers-10-top-gainers-and-losers-on-thursday-june-13th/">Today's Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Thursday</a> appeared first on <a href="https://investorplace.com">InvestorPlace</a>.

Today's Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Thursday

Petros Pharmaceuticals (PTPI – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst yesterday. Analyst Naz Rahma...

Buy Rating Affirmed for Petros Pharmaceuticals Amidst Promising Web App Technology and Strategic Advancements

<a href="https://investorplace.com">InvestorPlace - Stock Market News, Stock Advice &amp; Trading Tips</a>
Petros Pharmaceuticals (NASDAQ:<a href="https://investorplace.com/stock-quotes/ptpi-stock-quote/">PTPI</a>) just reported results for the second quarter of 2024.<ul><li>Petros Pharmaceuticals reported earnings per share of -37 cents. This was above the analyst estimate for EPS of -77 cents.</li><li>The company reported revenue of $1.42 million.</li><li>This was 1.50% better than the analyst estimate for revenue of $1.40 million.</li></ul><div>InvestorPlace Earnings is a project that leverages data from <a href="https://www.tradesmith.com">TradeSmith</a> to automate coverage of quarterly earnings reports. InvestorPlace Earnings distills key takeaways including earnings per share and revenue, as well as how a company stacks up to analyst estimates. These articles are published without human intervention, allowing us to inform our readers of the latest figures as quickly as possible. To report any concerns or inaccuracies, please contact us at <a href="mailto:editor@investorplace.com">editor@investorplace.com</a>.</div><h3>More From InvestorPlace</h3>
		<ul><li>
						<a href="https://investorplace.com/2024/04/legendary-investor-predicts-forget-a-i-this-technology-is-the-future/?cid=MKT794457&amp;eid=MKT802109">Legendary Investor Predicts: &ldquo;Forget AI... THIS Technology Is the Future&rdquo;</a>
					</li>
									</ul>The post <a href="https://investorplace.com/earning-results/2024/08/ptpi-stock-earnings-petros-pharmaceuticals-for-q2-of-2024/">PTPI Stock Earnings: Petros Pharmaceuticals Beats EPS, Beats Revenue for Q2 2024</a> appeared first on <a href="https://investorplace.com">InvestorPlace</a>.

PTPI Stock Earnings: Petros Pharmaceuticals Beats EPS, Beats Revenue for Q2 2024

Maxim Group analyst Naz Rahman reiterated a Buy rating on Petros Pharmaceuticals (PTPI – Research Report) yesterday. The company's shares closed ye...

Maxim Group Sticks to Its Buy Rating for Petros Pharmaceuticals (PTPI)

Analyst Naz Rahman from Maxim Group reiterated a Buy rating on Petros Pharmaceuticals (PTPI – Research Report) and decreased the price target to $1...

Positive App Study Outcomes Enhance Prospects for Petros Pharmaceuticals' OTC Stendra

The latest update is out from Petros Pharmaceuticals ( ($PTPI) ). John Shulman and Greg Bradley, both members of the board of directors at Petros P...

Board Reshuffle at Petros Pharmaceuticals Following Resignations

An update from Petros Pharmaceuticals ( ($PTPI) ) is now available. Petros Pharmaceuticals has amended its employment agreement with President Fady...

Petros Pharmaceuticals Amends President's Employment Terms

AEMD

AVGO

CARA

EEIQ

IONM

JILL

LGVN

PRFX

PTPI

ROMA

SIFYR

SQNS

VSME

XPON

Contracts

Press Releases

Petros Pharmaceuticals Expands Online Distribution for Prescription STENDRA(R) (avanafil) Through New Agreement with Lemonaid Health

Petros Pharmaceuticals announces online distribution for lead ED product with Lemonaid Health

Lemonaid Health Now Offers Prescription ED Medication STENDRAⓇ Through Collaboration with Petros Pharmaceuticals

Petros Pharmaceuticals Launches U.S. Distribution of Prescription ED Medication STENDRA Through Recently Announced Collaboration With Lemonaid Health, a Subsidiary of 23andMe

Petros Pharmaceuticals Activates Advisory Committee to Help Guide Rx-to-OTC Switch for STENDRA

Petros Pharmaceuticals Successfully Completes AI-Integrated Formative Human Factors Study Demonstrating Positive Interaction with Web App Designed for STENDRA(R) (avanafil) OTC Switch

Petros Pharmaceuticals' STENDRA(R) (avanafil) Pivotal Consumer Self-Selection Study for Over-the-Counter Access Demonstrates Statistical Significance

Petros Pharmaceuticals' Pivotal Statistically Significant Self Selection Study Shows Stronger Results with Proprietary Technology Application as Part of FDA Pathway for Over-the-Counter Access for STENDRA(R) (avanafil)

Events

Petros Pharmaceuticals to Present at the H.C. Wainwright 26th Annual Global Investment Conference

Petros Pharmaceuticals Executes Successful Initial Test for App Comprehension as Part of FDA Pathway for Over-the-Counter Access for STENDRA(R) (avanafil)

Comments

Petros Pharma

Vendite allo scoperto

Petros Pharma (NASDAQ:PTPI) Azioni, Report sulle vendite allo scoperto

Le persone guardano anche

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO